The stock of Xbiotech Inc (NASDAQ:XBIT) registered an increase of 22.71% in short interest. XBIT’s total short interest was 2.12M shares in October as published by FINRA. Its up 22.71% from 1.73M shares, reported previously. With 184,300 shares average volume, it will take short sellers 12 days to cover their XBIT’s short positions. The short interest to Xbiotech Inc’s float is 16.15%.
The stock increased 3.00% or $0.25 during the last trading session, reaching $8.58. About 109,537 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 58.92% since October 11, 2018 and is uptrending. It has outperformed by 58.92% the S&P500.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $351.88 million. The company??s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Globenewswire.com which released: “Dr. Seth Forman to Chair XBiotech’s Second Phase 2 Study of Bermekimab in Atopic Dermatitis – GlobeNewswire” on July 11, 2019, also Finance.Yahoo.com with their article: “Are Investors Undervaluing Autoneum Holding AG (VTX:AUTN) By 27%? – Yahoo Finance” published on August 19, 2019, Globenewswire.com published: “XBiotech Announces Addition of Top Dermatologist and Researcher Dr. Alice Gottlieb to its Team – GlobeNewswire” on September 20, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Investorplace.com and their article: “5 Growthy Biotech Stocks to Buy Despite the Scrutiny – Investorplace.com” published on May 13, 2019 as well as Benzinga.com‘s news article titled: “Mid-Day Market Update: Crude Oil Down 2.9%; Stellar Biotechnologies Shares Spike Higher – Benzinga” with publication date: May 31, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.